Holmium

Diagnostic Patch Testing

For the diagnosis of metal hypersensitivity, a standardized concentration of Holmium Chloride (usually 1.0% in petrolatum) is applied to the skin using specialized chambers (e.g., Finn Chambers). The dose is localized to a small area (approx. 8mm diameter) on the upper back.

Selective Internal Radiation Therapy (SIRT)

The dosage of Holmium-166 is not measured in milligrams but in radioactivity (Gigabecquerels, GBq). The prescribed activity is calculated based on the patient's liver volume, the tumor-to-normal tissue ratio, and the desired radiation dose (typically 60 Gy for the whole liver or higher for targeted segments). A common dose range is 1.0 to 8.0 GBq per treatment session.

Holmium is not routinely approved for pediatric use in either diagnostic or therapeutic capacities. Safety and efficacy have not been established in patients under the age of 18. In rare cases where a pediatric patient requires SIRT, the dosage must be strictly individualized based on body surface area and organ volume by a specialized pediatric oncologist and nuclear medicine physician.

Renal Impairment

For diagnostic patch testing, no adjustment is required. For Holmium-166 therapy, severe renal impairment may increase the risk of toxicity if there is significant extra-hepatic shunting, although the microspheres themselves are not cleared renally. Caution is advised in patients with a GFR < 30 mL/min.

Hepatic Impairment

Hepatic impairment is a critical factor for Holmium-166. Patients with Child-Pugh Class B or C may be at increased risk for Radioembolization-Induced Liver Disease (REILD). Dosage reduction or avoidance is often necessary if bilirubin levels exceed 2.0 mg/dL.

Elderly Patients

No specific dosage adjustments are required for elderly patients, though healthcare providers must account for the higher prevalence of pre-existing renal and hepatic decline in this population.

For Patch Testing

1. 1The skin on the back must be clean and dry.
2. 2The patch is applied and must remain in place for 48 hours.
3. 3Patients must avoid moisture (showering, sweating) and friction on the area during the test period.
4. 4The patch is removed by a clinician at 48 hours, with a final reading often performed at 72 or 96 hours.

For Holmium-166 SIRT

1. 1This is a surgical procedure performed by an interventional radiologist.
2. 2A catheter is inserted into the femoral artery and guided to the hepatic artery.
3. 3A "scout dose" (often using Technetium-99m or a small dose of Holmium-166) is given first to check for lung shunting.
4. 4The therapeutic dose is then infused slowly over several minutes.

In the context of SIRT, a missed dose is rare as it is a scheduled hospital procedure. If a procedure is delayed, it must be rescheduled immediately to account for the radioactive decay of the Holmium-166, which has a short half-life. For patch testing, if a patient misses the removal appointment, they should contact their dermatologist immediately; leaving the patch on too long can cause severe irritation.

Signs of Overdose (Radioactive Holmium)

• Acute radiation syndrome (nausea, vomiting, diarrhea).
• Severe bone marrow suppression (low white blood cell count).
• Acute liver failure.

Emergency Measures

In the event of an accidental overdose of Holmium-166, treatment is supportive. Chelating agents like DTPA (diethylenetriaminepentaacetic acid) may be considered to accelerate the excretion of soluble Holmium, though they are less effective for microspheres. Patients must be monitored in a specialized radiation unit.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

When used as a Standardized Chemical Allergen for patch testing, the most common side effect is localized skin irritation. This may manifest as:

• Erythema (Redness): A mild to moderate red spot at the site of application.
• Pruritus (Itching): A persistent urge to scratch the test site, which usually subsides after the patch is removed.
• Papules: Small, raised bumps that indicate a positive allergic reaction.

For Holmium-166 SIRT, common side effects (often referred to as Post-Radioembolization Syndrome) include:

• Abdominal Pain: Often felt in the upper right quadrant, occurring shortly after the infusion.
• Nausea and Vomiting: Typically lasting 24–48 hours post-procedure.
• Fatigue: A profound sense of tiredness that can persist for several weeks as the body processes the radiation effects.
• Low-Grade Fever: A transient increase in body temperature as the tumor tissue undergoes necrosis (cell death).

• Liver Enzyme Elevation: Transient increases in ALT, AST, and bilirubin levels.
• Anorexia: Loss of appetite following the SIRT procedure.
• Gastritis: Inflammation of the stomach lining if microspheres accidentally migrate to the gastric arteries.
• Leukopenia: A temporary drop in white blood cell counts.

• Radiation Pneumonitis: Inflammation of the lungs caused by "shunting," where microspheres bypass the liver and lodge in the pulmonary vasculature.
• Gastrointestinal Ulceration: Severe ulcers in the stomach or duodenum if there is significant non-target embolization.
• Anaphylaxis: A severe, life-threatening allergic reaction to the Holmium salt or the microsphere components.
• Permanent Skin Discoloration: At the site of a patch test in highly sensitive individuals.

> Warning: Stop taking Holmium and call your doctor immediately if you experience any of these.

• Signs of Liver Failure: Yellowing of the eyes or skin (jaundice), dark urine, or severe swelling in the abdomen (ascites).
• Severe Abdominal Pain: Which may indicate a perforated ulcer or acute pancreatitis.
• Shortness of Breath: Sudden onset of coughing or difficulty breathing, which could indicate radiation lung injury.
• Infection Signs: High fever, chills, or severe weakness, suggesting bone marrow suppression.

With Holmium-166, the primary long-term concern is Radioembolization-Induced Liver Disease (REILD). This condition can develop weeks or months after treatment and is characterized by non-malignant ascites and liver dysfunction. There is also a theoretical long-term risk of secondary malignancies due to radiation exposure, although this is rarely observed in the context of treating advanced liver cancer. For diagnostic Holmium, there are no known long-term systemic side effects once the localized skin reaction has healed.

Currently, there are no specific FDA Black Box Warnings for Holmium as a chemical allergen. However, for Holmium-166 microspheres, warnings are centered on:

1. 1Radiopharmaceutical Risk: Must be handled only by authorized professionals in licensed facilities.
2. 2Non-Target Embolization: Strict adherence to vascular mapping is required to prevent severe gastric or pulmonary injury.

Report any unusual symptoms to your healthcare provider.

Holmium is a specialized chemical and radioactive agent that requires strict medical supervision. Patients undergoing Holmium-based procedures must be aware of the specific risks associated with lanthanide exposure and ionizing radiation. It is essential to disclose all prior history of metal allergies, especially to other rare earth elements like Gadolinium or Lanthanum.

No FDA black box warnings for Holmium in its standardized chemical allergen form. However, therapeutic radioactive Holmium products carry significant warnings regarding the risk of permanent organ damage if the drug is misdirected during administration.

• Allergic Reactions / Anaphylaxis Risk: While Holmium is used to diagnose allergies, it can itself cause an acute anaphylactic response in rare cases. Patients with a history of multiple metal sensitivities should be monitored closely during patch testing.
• Hepatotoxicity: In SIRT, the primary risk is radiation-induced liver damage. Patients with pre-existing cirrhosis or hepatitis are at a significantly higher risk. Liver function tests must be performed weekly for the first month following treatment.
• Nephrotoxicity: Although Holmium is generally not nephrotoxic in the microsphere form, soluble Holmium salts can accumulate in the kidneys. Patients with chronic kidney disease (CKD) require careful monitoring of GFR.
• Radiation Safety: Patients receiving Holmium-166 must follow strict radiation safety protocols for several days post-treatment to avoid exposing family members to radiation. This includes sleeping in a separate bed and avoiding close contact with children and pregnant women.

• Liver Function Tests (LFTs): ALT, AST, Bilirubin, and Alkaline Phosphatase levels must be checked prior to and periodically after SIRT.
• Complete Blood Count (CBC): To monitor for potential bone marrow suppression (anemia, leukopenia, thrombocytopenia).
• Imaging: Post-procedure MRI or SPECT/CT scans are mandatory to confirm the distribution of Holmium-166 microspheres.
• Skin Assessment: For patch testing, the site must be evaluated by a dermatologist at specific intervals (48h and 72-96h).

There is no evidence that diagnostic Holmium affects the ability to drive. However, patients who have just undergone a SIRT procedure may experience significant fatigue or nausea and should not drive or operate heavy machinery for at least 48 to 72 hours post-procedure.

Alcohol should be strictly avoided for at least one week following Holmium-166 SIRT, as alcohol can exacerbate liver stress and interfere with the assessment of post-procedural liver function. For patch testing, alcohol has no known interaction, though excessive consumption may increase skin flushing and complicate the reading of the test.

Diagnostic Holmium is a one-time application. For therapeutic Holmium, the treatment is typically a single or limited-repeat session. There is no "withdrawal" syndrome, but the effects of the radiation are permanent and cannot be reversed once the microspheres are administered.

> Important: Discuss all your medical conditions with your healthcare provider before starting Holmium.

• Strong Chelating Agents (e.g., Edetate Disodium/EDTA): If administered systemically, chelators can bind to Holmium ions, altering their distribution and potentially causing rapid renal deposition and damage. This is particularly dangerous with radioactive Holmium.
• Other Lanthanide-Based Contrast Agents: Using Holmium concurrently with Gadolinium-based contrast agents may increase the risk of systemic lanthanide toxicity or interfere with MRI-based dosimetry.

• Hepatotoxic Medications: Drugs such as high-dose Acetaminophen, Amiodarone, or Methotrexate should be used with extreme caution following Holmium-166 SIRT, as the liver's capacity to metabolize these drugs may be compromised by radiation.
• Anticoagulants (e.g., Warfarin, Rivaroxaban): During the SIRT procedure, the use of anticoagulants increases the risk of bleeding at the arterial puncture site. These medications are typically paused prior to the procedure.

• Diuretics: May affect the volume status of the patient and the concentration of Holmium salts in the renal tubules, potentially increasing the risk of mild nephrotoxicity.
• Corticosteroids: While often used to manage side effects, systemic steroids can suppress the immune response needed for an accurate diagnostic patch test, potentially leading to a false-negative result.

• High-Fat Meals: There are no known direct interactions between food and Holmium, as Holmium is not administered orally. However, a light diet is recommended prior to SIRT to minimize nausea.
• Grapefruit Juice: Does not interact with Holmium as it does not utilize the CYP3A4 pathway.

• St. John’s Wort: While it affects many drugs, it has no known interaction with Holmium.
• Milk Thistle (Silybum marianum): Some patients use this for "liver support." While not contraindicated, patients should inform their doctor, as it could theoretically mask signs of radiation-induced liver enzyme elevation.
• Calcium Supplements: High doses of calcium might theoretically compete with Holmium ions for binding sites in experimental settings (related to its EPC as a Calcium-like agent), but this is not clinically significant for patch testing.

• MRI Interference: Because Holmium is paramagnetic, it will cause significant signal voids or artifacts on MRI scans. This is used therapeutically for visualization but can interfere with other diagnostic MRI interpretations in the abdominal area.
• Serum Calcium Tests: In rare cases of systemic absorption, lanthanides can cause falsely low calcium readings in certain colorimetric laboratory assays.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Known Hypersensitivity: Patients with a documented severe allergy to Holmium or other lanthanides (e.g., Gadolinium, Lanthanum) must never undergo Holmium-based testing or therapy. The mechanism is the risk of immediate anaphylaxis.
• Pregnancy: Therapeutic Holmium-166 is absolutely contraindicated in pregnancy due to the high risk of fetal radiation exposure and teratogenicity.
• Severe Lung Shunting: For SIRT, if the pre-treatment scout dose shows significant shunting to the lungs (>20% or a dose >30 Gy to the lungs), Holmium-166 is contraindicated to prevent radiation pneumonitis.
• Uncorrectable Coagulopathy: Because SIRT requires arterial catheterization, patients with severe bleeding disorders that cannot be corrected are excluded from treatment.

• Active Infection: Patch testing should be delayed until systemic or localized skin infections have resolved to avoid confounding the results.
• Ascites or Liver Failure: Patients with Child-Pugh Class C liver disease require an intensive risk-benefit analysis, as SIRT may precipitate terminal liver failure.
• Prior External Beam Radiation: If the patient has already received significant radiation to the liver, the cumulative dose from Holmium-166 may exceed safe limits.

Patients allergic to Holmium may show cross-sensitivity to other members of the lanthanide series, including:

• Gadolinium (used in MRI contrast)
• Lanthanum (used as a phosphate binder)
• Cerium (used in some topical burn creams)

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Holmium.

Holmium-166 is classified as FDA Pregnancy Category X. Radioactive isotopes cross the placenta and can cause fetal death, severe structural malformations, and childhood cancers. Women of childbearing potential must have a confirmed negative pregnancy test within 24 hours prior to receiving Holmium-166. For diagnostic patch testing, it is generally recommended to delay testing until after pregnancy unless the information is critical for managing severe dermatitis.

It is unknown if elemental Holmium is excreted in human milk. However, radioactive Holmium-166 poses a direct radiation risk to the nursing infant. Breastfeeding must be discontinued for a specific period (usually at least 2 weeks or until radioactivity is undetectable) following SIRT. For patch testing, the risk is minimal, but the site should be covered to prevent the infant from coming into contact with the allergen.

The safety and effectiveness of Holmium in children have not been established. Use in pediatric populations is considered off-label and is generally restricted to life-threatening oncological cases where no other options exist. There is a theoretical concern regarding the effect of lanthanides on bone growth in developing children.

Clinical trials of Holmium-166 SIRT included a significant number of patients aged 65 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients. However, elderly patients are more susceptible to Post-Radioembolization Syndrome and should be monitored more frequently for dehydration and fatigue.

In patients with impaired renal function, the clearance of any systemically absorbed Holmium ions may be reduced. While the microsphere form is not cleared by the kidneys, any free Holmium-166 or soluble salts used in testing require caution. Dose adjustments for SIRT are not standardized for renal impairment but rely on the clinical judgment of the nuclear medicine team.

Hepatic impairment is the most significant factor in Holmium therapy. Patients with a total bilirubin > 2.0 mg/dL or those with significant portal hypertension are at increased risk of REILD. In these patients, a reduced activity dose or a lobar (rather than whole-liver) approach is often utilized.

> Important: Special populations require individualized medical assessment.

Holmium acts as a trivalent cation (Ho3+). Its primary pharmacological interest lies in its Calcium Mimicry. Due to its ionic radius being nearly identical to calcium, it can occupy calcium-binding sites on proteins and enzymes. In the context of its EPC as an Acetylcholine Release Inhibitor, it blocks the P/Q-type voltage-gated calcium channels at the neuromuscular junction, preventing the influx of calcium required for the fusion of synaptic vesicles with the presynaptic membrane.

In oncology, Holmium-166 acts via Beta-Emission Radiotoxicity. The beta particles emitted during the decay of 166Ho to 166Er (Erbium) create reactive oxygen species (ROS) and direct DNA damage within a 2.5mm radius, leading to localized tumor destruction.

• Onset of Action: For SIRT, the radiation effect begins immediately upon embolization. For patch testing, the immunological onset occurs over 48–72 hours.
• Duration of Effect: The radioactive effect of Holmium-166 lasts for approximately 5–7 days (5 half-lives). The diagnostic skin reaction can last for 1–2 weeks.
• Tolerance: No known tolerance develops to the physical radiation or the allergic hapten effect.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intra-arterial/Topical) |

| Protein Binding | >90% (as free ions in plasma) |

| Half-life (Physical) | 26.8 hours (166Ho) |

| Tmax | Immediate (SIRT) |

| Metabolism | None |

| Excretion | Renal (soluble salts), Fecal (trace) |

• Molecular Formula: Ho (Elemental), HoCl3 (Chloride salt)
• Molecular Weight: 164.93 g/mol
• Solubility: Holmium chloride is highly soluble in water; Holmium oxide is insoluble.
• Structure: A silvery-white, soft metal; trivalent in most compounds.

Holmium is part of the Lanthanide class of elements. It is therapeutically grouped with other radioisotopes like Yttrium-90 and Lutetium-177, and diagnostically grouped with other metal allergens like Nickel, Cobalt, and Chromium.